Agere Pharmaceutical’s predictive technologies and solubilization expertise rapidly advances and de-risks the discovery and development of BCS class II-IV compounds.

The Solution for Insoluble API

New chemical entities (NCEs) in modern discovery libraries and development programs have an ever-increasing number of non-conventional physical and chemical properties. Up to 70% of discovery compounds and 40% of pipeline candidates are insoluble in water. These promising molecules present unique formulation and development challenges.

Agere’s solubilization technologies are designed to rapidly identify, develop, and manufacture the optimized oral or parenteral formulation for your insoluble API. Our Solid Dispersion Platform™ and PareSol™ technology provide a comprehensive and cost-effective solution to oral and parenteral delivery, respectively. For discovery-stage compounds, Agere’s OraLead™ technology assists in the selection and advancement of optimum leads using solubilization technologies.

Agere also provides a comprehensive set of complimentary services directed at testing and advancing insoluble API, including prediction of in vivo performance, assessment and prediction of chemical and physical stability, process development and manufacturing, solid dosage form development, solid-state characterization, and a complete set of analytical services.